

Emerging infectious diseases vaccines



Translating science
into global health impact

IAVI is applying its extensive vaccine development expertise and working with a group of expert international partners to develop vaccines to prevent emerging infectious diseases (EIDs).

A proven platform approach to global health security

New medical countermeasures against EIDs are a priority for global health security. Most EIDs are zoonotic, meaning they originated in vertebrate animals and “jumped” to humans through a complex biological process known as spillover.¹ Spillover events are increasing over time, and if trends continue, the next pandemic will most likely be caused by a zoonotic virus.²

Since 2018, IAVI has been pursuing the development of EID vaccines, building on more than two decades of experience and international collaboration in HIV vaccine development. Today, our EID vaccine platform includes single-dose vaccine candidates to prevent zoonotic diseases caused by priority pathogens: Lassa virus, Marburg virus, Sudan virus, and Bundibugyo virus. These viruses have high case fatality rates, cause repeated outbreaks, and are likely to cause public health emergencies of international concern.

Using proven vaccine technology can accelerate vaccine development for outbreak pathogens.³ IAVI's EID vaccine candidates are based on a recombinant vesicular stomatitis virus (rVSV) vector similar to the technology underlying Merck's Ebola virus vaccine, ERVEBO[®], which is approved by the U.S. FDA and registered in more than a dozen countries.

Zoonotic spillover events in West Africa are estimated to at least double by 2070, owing to a constellation of interrelated factors.⁴

¹ <https://www.nature.com/articles/nature06536>

² <https://pubmed.ncbi.nlm.nih.gov/18288193>

³ [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(23\)00328-5/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00328-5/fulltext)

⁴ <https://www.nature.com/articles/s41467-022-33112-3>

EIDs by the numbers



~50%

average case fatality rate for Ebola virus and Marburg virus disease



100,000–300,000

cases of Lassa fever occur annually



15%

average case fatality rate for people hospitalized with Lassa fever



600%

increase in the number of people exposed to Lassa virus by 2070⁴



100%

efficacy for Merck's rVSV-based Ebola Zaire vaccine (ERVEBO[®]) in a Phase 3 trial, the technology for which is the basis of IAVI's VSV platform



4

IAVI EID vaccines in the product development pipeline

IAVI's rVSV EID vaccine platform

- Based on licensed Ebola vaccine technology.
- Elicits an immune response in just one dose.
- State-of-the-art modular manufacturing for vaccine production.
- Reduced infrastructure requirements and streamlined, low-cost production suitable for unpredictable EID outbreaks.
- Potential for multivalent EID vaccine development.

IAVI's Vaccine Design and Development Lab

Much of the research and development on IAVI's rVSV platform is performed at IAVI's Vaccine Design and Development Lab (DDL) in Jersey City, New Jersey. Since its founding in 2008 the DDL has become one of the world's leading viral vector vaccine research and development labs, known for innovation and generation of novel vaccine design concepts. The DDL's Biosafety Level (BSL) 2 laboratories are outfitted for molecular cloning, cell culture, virology, protein chemistry, and immunology research.

IAVI's EID vaccine candidates			
Vaccine	Funder/partner	Stage	Status
Lassa virus rVSVΔG-LASV-GPC*	Coalition for Epidemic Preparedness Innovations (CEPI); European & Developing Countries Clinical Trials Partnership (EDCTP)	Phase 2	European Medicines Agency <u>Priority Medicines status</u> ; 2025
Marburg virus rVSVΔG-MARV-GP*	Biomedical Advanced Research and Development Authority (BARDA); U.S. Department of Defense – Defense Threat Reduction Agency	Phase 1	<u>Short-listed</u> by WHO for ring vaccination in Uganda; 2024
Sudan virus rVSVΔG-SEBOV-GP*	Biomedical Advanced Research and Development Authority (BARDA)	Phase 1	<u>Prioritized</u> by WHO for evaluation in ring vaccination trial in Uganda; 2022. <u>Deployed</u> in efficacy ring vaccination trial in Uganda in response to outbreak; 2025.
Sudan virus rVSVΔG-SUDV-GP*	Biomedical Advanced Research and Development Authority (BARDA)	Phase 1	Being evaluated at sites in the U.S.
Bundibugyo virus rVSVΔG-BDBV-GP*	Coalition for Epidemic Preparedness Innovations (CEPI)	Preclinical	<u>Identified</u> by WHO as the most promising candidate for epidemic in the DRC and Uganda; 2026.

*Technology licensed from the Public Health Agency of Canada.

IAVI gratefully acknowledges the generous support provided by the following major funders:



Biomedical Advanced Research and Development Authority (BARDA) | Foundation for the National Institutes of Health | National Institute of Allergy and Infectious Diseases | amfAR, The Foundation for AIDS Research | Broadway Cares/Equity Fights AIDS | The City of New York, Economic Development Corporation | Congressionally Directed Medical Research Program (DoD) | GSK | The Hearst Foundations | Keith Haring Foundation | Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the USA and Canada)

And many other generous individuals and partners around the world

As of January 2026